Why the study?
ABPM is considered the best means of diagnosing hypertension but is rarely used and reimbursed under narrow conditions; the study sought stakeholder insight to inform the first CMS policy revision in over 15 years.
Qualitative analysis of public comments to CMS reveals broad stakeholder support for expanding Medicare reimbursement coverage for ambulatory blood pressure monitoring.
Broad stakeholder support for expanded CMS ABPM coverage; leaves open effects on hypertension outcomes and equitable access in Medicare populations.
Ambulatory blood pressure monitoring (ABPM) is considered the best means of diagnosing hypertension. However, it is rarely used and is reimbursed only under narrow conditions. We sought to gain insight into the perceived value of ABPM among stakeholders who responded to the Centers for Medicare and Medicaid Services' (CMS) request for comments to inform the first revision of ABPM reimbursement policy in over 15 years. We found that most comments were classifiable in two main themes, current coverage and future coverage. Individuals and institutions representing multiple disciplines and specialties were highly supportive of expanding the current CMS coverage of ABPM, including for a wide range of clinical indications and populations. It is clear from the comments reviewed that there is wide support for expanding CMS coverage for ABPM. Broad support for a change in ABPM reimbursement policy may lead to changes in the way this technology is used in the United States.
No takes yet. Share an insight, caveat, or question.
Dixon et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: